Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SLS

SELLAS Life Sciences Group Inc

Jun 18 • 04:00PM ET

1.57

Dollar change +0.01
Percentage change 0.64	%

Healthcare • Biotechnology • USA • NASD

Peers: TGTX KPTI IMMP AFMD ADAP BCRX ACET AVDL TLSA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.39	Insider Own	2.11%	Shs Outstand	99.78M	Perf Week	4.67%
Market Cap	156.65M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	2.43%	Shs Float	97.67M	Perf Month	-10.29%
Income	-27.13M	PEG	-	EPS next Q	-0.08	Inst Own	14.33%	Short Float	12.51%	Perf Quarter	29.75%
Sales	0.00M	P/S	-	EPS this Y	36.67%	Inst Trans	8.10%	Short Ratio	5.95	Perf Half Y	80.03%
Book/sh	0.31	P/B	5.14	EPS next Y	-20.00%	ROA	-91.36%	Short Interest	12.22M	Perf Year	4.67%
Cash/sh	0.29	P/C	5.50	EPS next 5Y	33.56%	ROE	-144.90%	52W Range	0.77 - 2.12	Perf YTD	50.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	45.94%	ROIC	-96.65%	52W High	-25.94%	Beta	2.27
Dividend TTM	-	Quick Ratio	4.64	Sales past 5Y	-	Gross Margin	-	52W Low	103.37%	ATR (14)	0.13
Dividend Ex-Date	Mar 24, 2011	Current Ratio	4.64	EPS Y/Y TTM	64.62%	Oper. Margin	-	RSI (14)	47.75	Volatility	2.15% 5.21%
Employees	15	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	5.83
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	68.99%	Payout	-	Rel Volume	1.23	Prev Close	1.56
Sales Surprise	-	EPS Surprise	33.33%	Sales Q/Q	-	Earnings	May 13 AMC	Avg Volume	2.05M	Price	1.57
SMA20	-5.42%	SMA50	2.27%	SMA200	24.27%	Trades		Volume	2,525,028	Change	0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-21	Initiated	Cantor Fitzgerald	Overweight	$18
Nov-01-18	Initiated	Oppenheimer	Outperform
Apr-02-18	Initiated	H.C. Wainwright	Buy	$11
Mar-19-18	Upgrade	Maxim Group	Hold → Buy	$13

Jun-05-25 08:45AM	SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts (GlobeNewswire)
Jun-02-25 08:00AM	SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting (GlobeNewswire) -7.60%
May-21-25 06:00AM	Solaris Enters into US$200 Million Financing Agreements with Royal Gold to Advance the Warintza Project (GlobeNewswire) -12.37%
May-20-25 08:00AM	SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase (GlobeNewswire) +10.86%
May-15-25 08:45AM	SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML (GlobeNewswire) +5.96%
04:05PM	Loading…
May-13-25 04:05PM	SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -8.44% +7.09%
Apr-28-25 08:45AM	SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference (GlobeNewswire)
Apr-23-25 10:23AM	SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-08-25 08:45AM	SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML (GlobeNewswire)
Apr-05-25 12:37PM	Undercovered Dozen: Power Metals, Verses AI, TFS Financial, Nextdoor + (Seeking Alpha)
Mar-31-25 03:03PM	Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (Seeking Alpha)
Mar-20-25 04:05PM	SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-21-25 07:29AM	Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment (Clinical Trials Arena)
Feb-20-25 08:45AM	SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL (GlobeNewswire)
03:11PM	Loading…
Jan-28-25 03:11PM	SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.02%
Jan-23-25 08:10AM	SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia (GlobeNewswire) -13.25%
Jan-08-25 08:20AM	SELLAS Announces Key Business Objectives for 2025 (GlobeNewswire) -9.49%
Jan-02-25 08:00AM	SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET (GlobeNewswire)
Dec-10-24 08:30AM	SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia (GlobeNewswire)
Dec-09-24 08:45AM	SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML (GlobeNewswire)
Nov-28-24 05:37AM	SELLAS announces data indicating key predictor of response to SLS009 in solid cancers (Clinical Trials Arena)
Nov-27-24 08:45AM	SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers (GlobeNewswire)
Nov-13-24 04:15PM	SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.93%
Nov-05-24 09:55AM	SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 (GlobeNewswire)
Oct-15-24 08:45AM	SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia (GlobeNewswire)
Oct-10-24 04:05PM	SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-18-24 03:09PM	Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory (Insider Monkey)
Aug-13-24 04:10PM	SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-24 08:45AM	SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas (GlobeNewswire)
08:30AM	Loading…
Jul-31-24 08:30AM	SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market (GlobeNewswire) -7.20%
Jul-16-24 09:05AM	SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia (GlobeNewswire)
Jul-08-24 08:45AM	SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia (GlobeNewswire)
Jun-24-24 09:05AM	SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia (GlobeNewswire)
Jun-17-24 09:45AM	Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase (GlobeNewswire) -16.67%
09:05AM	SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia (GlobeNewswire)
Jun-10-24 08:40AM	SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML (GlobeNewswire)
May-14-24 10:54PM	SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024 (InvestorPlace) +7.30%
04:05PM	SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-24 08:35AM	SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level (GlobeNewswire)
Apr-29-24 08:45AM	SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study (GlobeNewswire) -17.12%
Mar-28-24 10:54PM	SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023 (InvestorPlace) +5.94%
04:05PM	SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma (PR Newswire)
Mar-26-24 07:35AM	SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study (GlobeNewswire)
Mar-19-24 04:05PM	SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:47AM	SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET (GlobeNewswire)
Mar-15-24 09:00AM	SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -29.03%
Mar-08-24 08:00AM	SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships (GlobeNewswire)
Mar-01-24 08:30AM	SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference (GlobeNewswire)
Feb-29-24 08:00AM	SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time (GlobeNewswire)
Feb-06-24 08:30AM	SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget (GlobeNewswire) +12.24%
Jan-25-24 08:45AM	SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference (GlobeNewswire)
Jan-11-24 06:00AM	GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia (PR Newswire)
Jan-10-24 11:30AM	SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate (Zacks)
Jan-09-24 08:30AM	SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients (GlobeNewswire)
Jan-04-24 09:01AM	SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering (GlobeNewswire) -35.77%
08:41AM	Why Is Sellas Life Sciences (SLS) Stock Down 25% Today? (InvestorPlace)
Jan-03-24 08:05PM	SELLAS Life Sciences Announces Proposed Public Offering (GlobeNewswire)
07:30AM	SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-27-23 08:55AM	SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma (GlobeNewswire)
Dec-21-23 08:15AM	SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas (GlobeNewswire) -5.74%
Dec-14-23 08:30AM	SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia (GlobeNewswire) +14.15%
Dec-13-23 08:30AM	SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET (GlobeNewswire)
Dec-04-23 08:47AM	SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire)
Nov-29-23 08:45AM	SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire)
Nov-13-23 08:50AM	SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS) (GlobeNewswire)
Nov-09-23 04:04PM	SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:57AM	SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting (GlobeNewswire)
Oct-31-23 08:05AM	SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -16.37%
Oct-30-23 09:03AM	SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas (GlobeNewswire) +23.98%
Oct-17-23 08:45AM	SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting (GlobeNewswire) -7.87%
Oct-16-23 08:45AM	SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia (GlobeNewswire)
Oct-12-23 04:05PM	SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire) -10.42% +20.93%
Oct-11-23 08:30AM	SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas (GlobeNewswire) -15.49%
Oct-10-23 04:15PM	SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia (GlobeNewswire)
07:00AM	GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL) (PR Newswire)
Sep-21-23 08:30AM	SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met (GlobeNewswire) +6.67%
Sep-18-23 04:19PM	SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) -6.83%
Aug-22-23 08:30AM	SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications (GlobeNewswire)
Aug-10-23 04:08PM	SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-15-23 09:25AM	Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely (Simply Wall St.)
Jun-28-23 04:00PM	Survival Rates Improve with SELLAS's New Treatment for Severe Lung Cancer, Phase 1 Study Shows (Benzinga)
08:30AM	SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma (GlobeNewswire)
Jun-22-23 08:45AM	SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia (GlobeNewswire)
Jun-15-23 04:05PM	SELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting (GlobeNewswire)
Jun-13-23 08:30AM	SELLAS to Participate in Maxim Group Healthcare Virtual Conference (GlobeNewswire)
May-25-23 05:05PM	SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting (GlobeNewswire) +7.01%
May-16-23 08:30AM	SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia (GlobeNewswire)
May-11-23 04:12PM	SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire) -11.11%
May-04-23 08:30AM	SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study (GlobeNewswire)
Apr-26-23 04:01PM	SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting (GlobeNewswire) +5.04%
Apr-20-23 08:30AM	SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia (GlobeNewswire) -5.77%
Apr-18-23 08:30AM	SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned (GlobeNewswire)
Mar-16-23 04:11PM	SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-23 08:30AM	SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal (GlobeNewswire)
Feb-24-23 08:42AM	Sellas Life Sciences raises $20 million from public offering of stock, warrants (MarketWatch) -53.66%
08:30AM	SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering (GlobeNewswire)
07:29AM	Sellas Lift Sciences stock plunges to pace premarket decliners after stock, warrants offering (MarketWatch)
Feb-23-23 04:01PM	SELLAS Life Sciences Announces Proposed Underwritten Public Offering (GlobeNewswire)

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VAN NOSTRAND ROBERT L	Director	Jun 12 '25	Buy	1.48	10,000	14,800	20,400	Jun 13 08:00 AM
Wasman Jane	Director	May 30 '25	Buy	1.69	20,000	33,800	30,400	Jun 02 04:42 PM
Kalin Katherine Bach	Director	May 22 '25	Buy	1.80	20,000	36,000	41,000	May 22 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLS

SELLAS Life Sciences Group Inc

Upgrade your FINVIZ experience